- Antibodies
- New
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Tag
- Peptides
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Amino Acids
- Tag
- Biological Process >
- Proteins
- RNAi
- FL cDNA Clones
- Cell/Tissues/Lysates
Myb Sumoylation Site AntibodyPeptide Affinity Purified Rabbit Polyclonal Antibody (Pab)
| Country | United States
Ordering Information
|
|||
|---|---|---|---|---|
| Catalog # | Size | Availability | Price | |
| AP2500a | 0.1 mg 400 ul | In Stock | $ 255.00 | DISCONTINED INQUIRE CLICK INQUIRE Add to cart |
| AP2500a-ev20 | 20 ug 100 ul | In Stock | $ 95.00 | DISCONTINED INQUIRE CLICK INQUIRE Add to cart |
- Specification
- Citiations : 0
- Reviews
- Protocols
- Backgrounds
Myb Sumoylation Site Antibody - Product info | |
| Application | IHC, WB
|
| Primary Accession | P10242 |
| Reactivity | Mouse |
| Concentration | 0.25 mg/ml |
| Isotype | Rabbit Ig |
| Calculated MW | 72341 Da |
Myb Sumoylation Site Antibody - Additional info | |
| Gene ID 4602 | |
| Other Names MYB; Transcriptional activator Myb; Proto-oncogene c-Myb | |
| Target/Specificity This Myb Sumoylation Site antibody is generated from rabbits immunized with the KLH conjugated synthetic peptide PLLKKIKQEVESPTCA containing a predicted sumoylation site from the C-terminal region of human HSF2. | |
| Dilution IHC~~1:50~100 WB~~1:100~500WB~~1:1000 | |
| Format Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification. | |
| Storage Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. | |
| Precautions Myb Sumoylation Site Antibody is for research use only and not for use in diagnostic or therapeutic procedures. | |
Myb Sumoylation Site Antibody - Protein Information | |
| Name MYB | |
| Function Transcriptional activator; DNA-binding protein that specifically recognize the sequence 5'-YAAC[GT]G-3'. Plays an important role in the control of proliferation and differentiation of hematopoietic progenitor cells | |
| Cellular Location Nucleus. | |
Myb Sumoylation Site Antibody - Related products
Myb Sumoylation Site Antibody - Application data
-
Formalin-fixed and paraffin-embedded human cancer tissue reacted with the primary antibody, which was peroxidase-conjugated to the secondary antibody, followed by DAB staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated. BC = breast carcinoma; HC = hepatocarcinoma.
-
Myb Antibody (Sumo) (Cat. #AP2500a) western blot analysis in mouse heart tissue lysates (35ug/lane).This demonstrates the Myb antibody detected the Myb protein (arrow).
Myb Sumoylation Site Antibody - Research Areas
Abgent welcomes feedback from its customers.
If you have used an Abgent product and would like to share how it has performed, please click on the
"Submit Review" button and provide the requested information. Our staff will examine and post your
review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abgent.com.
Thank you for your support.
Provided below are standard protocols that you may find useful for product applications.
BACKGROUND
Myb is a transcriptional activator; DNA-binding protein that recognizes the sequence 5'-YAAC[GT]G-3'. It participates in the control of proliferation and differentiation of hematopoietic progenitor cells. Myb is a transcription factor related to Myc, and is expressed predominantly in haematopoietic cells and immature gastroepithelial cells. TRAF7 stimulates the sumoylation of Myb at Lys-523 and Lys-499, which are the same sites as those used for PIASy-induced sumoylation. A correlation has been established between reduction in sumoylation of Myb and increase in transcriptional activation. Negative influence on transactivation properties by the negative regulatory domain region of c-Myb depends on upon sumoylation.
REFERENCES
Luchetti, M.M., et al., J. Biol. Chem. 278(3):1533-1541 (2003). Dahle, O., et al., Eur. J. Biochem. 270(6):1338-1348 (2003). Chen, J., et al., Oncogene 21(12):1859-1869 (2002). Hernandez-Munain, C., et al., J. Immunol. 169(8):4362-4369 (2002). Tanno, B., et al., J. Biol. Chem. 277(26):23172-23180 (2002).